Germline BRCA-Mutated Metastatic Breast Cancer

For patients with metastatic breast cancer who carry germline BRCA1 or BRCA2 pathogenic variants, oral PARP inhibitors have shown activity. BRCA1 and BRCA2 are tumor suppressor genes that encode proteins involved in DNA repair (via the homologous recombination repair pathway). PARP plays a critical role in DNA repair and has been studied as therapy for patients with breast cancer who harbor germline BRCA1 or BRCA2 variants.